Gastric Malignancies

Latest Articles

Improved Psychological Support Needed After Stoma Surgery

By

Jessica Nye, PhD

Interview study identified categories in which improved psychological support services are needed for these patients.

First Surveillance Endoscopy Three Years After Atrophic Gastritis Diagnosis Appears Safe

By

Colby Stong

Investigators of the longitudinal cohort study evaluated follow-up gastroscopy results from patients who underwent surveillance 3 years after receiving a diagnosis of autoimmune or multifocal atrophic gastritis.

Delayed Cancer Screenings and Treatment Threaten Progress in Cancer Mortality Rates

By

Tara Haelle

If the current COVID-19 trends persist, the NCI estimates that the pandemic’s impact could threaten the trend of annually decreasing cancer mortality seen in the US since 1990.

Targeted Therapies, Immunotherapies, Immunomodulators: A Guide to Cancer Therapies

By

Katarina Zimmer, MSci, MS

Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.

Vitamin D Supplementation Associated With Reduced Incidence of Advanced Cancer

Vitamin D supplementation was associated with a reduction in the incidence of advanced cancer, with the strongest reduction seen in those with normal weight.

Full JAVELIN Gastric 100 Dataset Published

By

Rachel Narozniak, MA

Data from the phase-3 investigation of avelumab vs chemotherapy as maintenance therapies for the treatment of gastric or gastroesophageal junction cancer were published in the Journal of Clinical Oncology.

Bemarituzumab, Chemotherapy Improve Survival in FGFR2b-Positive Gastric/GEJ Cancer

By

Rachel Narozniak, MA

Five Prime Therapeutics, Inc. announced topline data from the phase 2 FIGHT study comparing bemarituzumab and chemotherapy with chemotherapy alone.

LCI Detects Neoplasms in Upper GI Tract More Frequently Than WLI

By

Emily Pond

Investigators compared the efficacy of linked color imaging and white light imaging in detecting neoplastic lesions in the upper gastrointestinal tract.

Lack of Insurance Associated With Poor Gastric Cancer Survival Outcomes

By

Rachel Narozniak, MA

Investigators evaluated the impact of insurance status on gastric cancer survival outcomes in patients treated at a safety-net hospital.

HER2-Directed Treatment Gets Priority Review for HER2+ Metastatic Gastric or GEJ Adenocarcinoma

By

Brian Park, PharmD

The supplemental Biologics License Application includes data from the open-label, randomized phase 2 DESTINY-Gatric01 trial.

New Guidelines for Eradicating H pylori for GC Prevention

By

Jessica Nye, PhD

A global consensus meeting was convened to go over current evidence and knowledge gaps and propose collaborative studies on population-wide screening and eradication of Helicobacter pylori for the prevention of gastric cancer (GC).

Delays in Cancer Surgery Due to COVID-19 Could Harm Survival

Modest delays in cancer surgery due to the COVID-19 pandemic could have a significant impact on survival.

Family History-Based Early Screen Could Identify More Cases of Young-Onset CRC

About one in four cases of colorectal cancer in patients aged 40 to 49 years meet family history-based criteria for early screening.

Gastric Intestinal Metaplasia: 2020 AGA Guidelines

By

Andy Kistler, MD, PharmD

The American Gastroenterological Association recently published new clinical practice guidelines on the management of gastric intestinal metaplasia.

Value Pathways for Treatment Decisions in Gastric Cancer Had Little Impact on OS

By

Randi Hernandez

Although the use of value pathways in oncology appeared to extend time to treatment failure, it did not appear to influence overall survival.

PFS With Maintenance Therapy in Some Esophageal or Gastric Cancers May Be Linked to PD-L1 Level

By

Susan Moench, PhD, PA-C

In this interim analysis, PFS rates were compared in PD-L1–defined biomarker subsets of patients receiving maintenance durvalumab or capecitabine.

Stomach Virus Strikes 170 Yosemite Visitors, Staff

About 170 visitors and employees at Yosemite National Park have been hit by gastrointestinal illness, park officials say.

Ayvakit Approval for GI Stromal Tumor With PDGFRAM Mutation

By

Brian Park, PharmD

The FDA has approved Ayvakit (avapritinib; Blueprint Medicines Corporation), a tyrosine kinase inhibitor, for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.

“Unexpected” CDH1 Variants Lead to Uncertainty

By

Christina Bennett, MS

Unexpectedly identifying a patient as a CDH1 carrier can lead to a “difficult conundrum” for clinicians and patients, highlighting the need for pretest counseling.

Incidence of Early-Onset Gastric Cancer Increasing in the US

The incidence of early-onset gastric cancer has been increasing in the United States, and it seems to be distinct clinically and genetically from late-onset gastric cancer.